Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Leblanc

Showing results (11-20 of 153) with videos related to

Pageof 16
Sort By:
JCO Clinical Cancer Informatics|April 8, 2021
Accounting for All Patients in Waterfall PlotsJames Moon, Michael LeBlanc, Megan Othus
Statistical Methods in Medical Research|July 4, 2002
Partitioning and peeling for constructing prognostic groupsMichael LeBlanc, Joth Jacobson, John Crowley
Biostatistics (Oxford, England)|June 24, 2005
Extreme regressionMichael LeBlanc, James Moon, Charles Kooperberg
Biometrics|July 14, 2005
Adaptive risk group refinementMichael LeBlanc, James Moon, John Crowley
Genetic Epidemiology|September 16, 2010
Risk prediction using genome-wide association studiesCharles Kooperberg, Michael LeBlanc, Valerie Obenchain
Clinical Trials (London, England)|August 19, 2017
Comparisons of cancer staging systems should be based on overall performance in the populationKathleen F Kerr, Michael LeBlanc, Holly Janes
Biometrics|May 16, 2008
Semiparametric estimation exploiting covariate independence in two-phase randomized trialsJames Y Dai, Michael LeBlanc, Charles Kooperberg
Journal of the National Cancer Institute|June 29, 2011
More randomization in phase II trials: necessary but not sufficientLawrence Rubinstein, Michael Leblanc, Malcolm A Smith
Physical Review Letters|September 26, 2012
Distribution of maximum velocities in avalanches near the depinning transitionMichael LeBlanc, Luiza Angheluta, Karin Dahmen, et al.
Clinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.
Pageof 16

Showing results (11-20 of 153) with videos related to

Sort By:
Pageof 16
JCO Clinical Cancer Informatics|April 8, 2021
Accounting for All Patients in Waterfall PlotsJames Moon, Michael LeBlanc, Megan Othus
Statistical Methods in Medical Research|July 4, 2002
Partitioning and peeling for constructing prognostic groupsMichael LeBlanc, Joth Jacobson, John Crowley
Biostatistics (Oxford, England)|June 24, 2005
Extreme regressionMichael LeBlanc, James Moon, Charles Kooperberg
Biometrics|July 14, 2005
Adaptive risk group refinementMichael LeBlanc, James Moon, John Crowley
Genetic Epidemiology|September 16, 2010
Risk prediction using genome-wide association studiesCharles Kooperberg, Michael LeBlanc, Valerie Obenchain
Clinical Trials (London, England)|August 19, 2017
Comparisons of cancer staging systems should be based on overall performance in the populationKathleen F Kerr, Michael LeBlanc, Holly Janes
Biometrics|May 16, 2008
Semiparametric estimation exploiting covariate independence in two-phase randomized trialsJames Y Dai, Michael LeBlanc, Charles Kooperberg
Journal of the National Cancer Institute|June 29, 2011
More randomization in phase II trials: necessary but not sufficientLawrence Rubinstein, Michael Leblanc, Malcolm A Smith
Physical Review Letters|September 26, 2012
Distribution of maximum velocities in avalanches near the depinning transitionMichael LeBlanc, Luiza Angheluta, Karin Dahmen, et al.
Clinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.
Pageof 16